Candel Therapeutics
CADL
9.82
-0.05
-0.51%
Candel Therapeutics
US · CADL
#3461 by market cap
Listed 2021
9.82
-0.05
-0.51%
Live - 5344 symbols - heartbeat 327s ago
· 2026-10-08 09:13
Pre-market
9.82
-0.02%
After-hours
9.83
+0.10%
- Market cap
- 751.41M
- P/E (TTM)i
- -6.68
- P/Bi
- 5.96
- EPSi
- -0.72
- Div yieldi
- 0.00%
- 52W posi
- 57%
Reader sentiment
Are you bullish or bearish on CADL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 0.3 percentage points.
Institutional ownership
- Held by institutions
- 73.76% -0.28pp
- Institutions
- 165
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund39.24%
Hedge Fund20.64%
Individual/Insider7.57%
VC/PE Fund6.81%
Private Company5.78%
Public Company1.07%
Insurance Company0.18%
Other18.67%
Top holders as of 2026-06-30
FMR
14.36% · 10.99M sh
RTW Investments, LP
8.39% · 6.42M sh
BlackRock
6.49% · 4.97M sh
Paul Manning
5.81% · 4.44M sh
State Street Global Advisors
4.64% · 3.55M sh
Acorn Bioventures
4.57% · 3.50M sh
Portolan Capital Management, LLC
4.56% · 3.49M sh
Saturn V Capital Management LP
4.32% · 3.30M sh
Vanguard Capital Management, LLC
4.06% · 3.11M sh
Estuardo Aguilar-Cordova 2020 Irrevocable Trust
2.71% · 2.07M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 43 buys · 7 sells
| Name | Role | Stake |
|---|---|---|
| Paul Manning | Independent Chairperson | 5.81% |
| Christopher Martell | Independent Director | 0.97% |
| Estuardo Aguilar-Cordova | Founder | 0.16% |
| Paul-Peter Tak | Chief Executive Officer | 0.15% |
| Joseph Papa | Independent Director | 0.13% |
| Francesca Barone | Chief Scientific Officer | 0.10% |
| Seshu Tyagarajan | Chief Technical & Development Officer | 0.10% |
| William Garrett | Chief Medical Officer | 0.07% |
| Charles Schoch | Interim CFO, Principal Financial & Principal Accounting Officer | 0.06% |
| Diem Nguyen | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Joseph Papa | Independent Director | Other Derivative Acquisition | +1,325 | $10.44 |
| 2026-09-29 | Paul Manning | Independent Chairperson | Other Derivative Acquisition | +2,189 | $10.44 |
| 2026-09-29 | Nicoletta Loggia | Independent Director | Other Derivative Acquisition | +380 | $10.44 |
| 2026-09-10 | Paul-Peter Tak | Chief Executive Officer | Automatic Disposition | -155,245 | $10.46–11.50 |
| 2026-09-09 | Paul-Peter Tak | Chief Executive Officer | Derivative Exercise and Sale | -125,000 | $1.55–11.50 |
| 2026-09-07 | Martine Zimmermann | Independent Director | Other Derivative Acquisition | +64,000 | $12.60 |
| 2026-08-16 | Seshu Tyagarajan | Chief Technical & Development Officer | Automatic Disposition | -7,000 | $12.00 |
| 2026-06-29 | Joseph Papa | Independent Director | Other Derivative Acquisition | +1,331 | $10.30 |
| 2026-06-29 | Paul Manning | Independent Chairperson | Other Derivative Acquisition | +2,199 | $10.30 |
| 2026-06-29 | Nicoletta Loggia | Independent Director | Other Derivative Acquisition | +381 | $10.30 |
| 2026-06-28 | Francesca Barone | Chief Scientific Officer | Automatic Disposition | -23,447 | $10.06 |
| 2026-06-28 | Seshu Tyagarajan | Chief Technical & Development Officer | Automatic Disposition | -7,000 | $10.02 |
| 2026-06-22 | Joseph Papa | Independent Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Edward Benz | Member of Research Advisory Board & Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Paul Manning | Independent Chairperson | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Gary Nabel | Independent Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Renee Gaeta | Independent Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Mahalakshmi Radhakrishnan | Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Christopher Martell | Independent Director | Other Derivative Acquisition | +32,000 | $9.08 |
| 2026-06-22 | Diem Nguyen | Independent Director | Other Derivative Acquisition | +32,000 | $9.08 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:13:45 · For reference only, not investment advice and not tailored to your situation.